Total trials
113
Active
30
Phase 3
3
Total enrollment
52,133
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| probiotic containing L.rhamnosus R0011 strain | — | — | — | — | — | 2 | |
| semaglutide 1 mg weekly | — | — | — | — | — | 1 | |
| Semaglutide Injectable Product | — | — | — | — | — | 1 | |
| Tinzaparin | — | — | — | — | — | 1 | |
| enoxaparin | — | — | — | — | — | 1 |
Next readouts
- 2026-06
- 2026-08
- 2026-08-01
- 2026-08-31
- 2027-01
Top conditions
- Obesity4
- Aging4
- Appetite Loss4
- Obesity & Overweight3
- Sarcopenia3
- Exercise3
- Pain3
- Well-Being, Psychological3
Frequently asked questions about University College Dublin
- How many clinical trials does University College Dublin have on ClinicalTrials.gov?
- University College Dublin is listed as the lead sponsor on 113 clinical trials in ClinicalTrials.gov, 30 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University College Dublin's trials are in Phase 3?
- 3 of University College Dublin's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does University College Dublin focus on?
- University College Dublin's most-studied conditions on ClinicalTrials.gov are Obesity, Aging, Appetite Loss, Obesity & Overweight, Sarcopenia.
- When are University College Dublin's next clinical trial readouts?
- University College Dublin has 5 upcoming primary-completion readouts tracked here; the soonest is “Encapsulated Probiotics & Gut Microbiota”, expected around 2026-06.